A new article published in Current Opinion in Pediatrics discussed that allergic rhinoconjunctivitis is the most common manifestation of allergic disease. The disease causes a disruption in the natural function of the immune system, which then aggressively reacts to harmless irritants such as pollen and pet dander, and hence, leads to a substantial disease burden. The authors reported that individual molecular component testing may increase the predictive value of blood sIgE and clinical symptoms in the diagnosis of allergic rhinoconjunctivitis. While defining the most symptoms-inducing allergenic protein has led to advances in peptide-based allergen immunotherapy. In fact, consistent reports have suggested that allergy immunotherapy for children with symptomatic allergic rhinitis prevents the onset of asthma. This article inferred that allergy immunotherapy is an effective disease-modulating treatment that alters the underlying immune dysfunction, which is currently an underutilized therapy, more so because it could be effective in preventing the onset of asthma in children, at least in the short term.